Pure Bioscience Reports Definitive Agreement and Equity Sales
Ticker: PURE · Form: 8-K · Filed: Sep 20, 2024 · CIK: 1006028
| Field | Detail |
|---|---|
| Company | Pure Bioscience, Inc. (PURE) |
| Form Type | 8-K |
| Filed Date | Sep 20, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $500,000, $3.0 million, $0.095, $0.175 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financial-obligation
TL;DR
PURE just signed a big deal and sold some stock, watch out for dilution!
AI Summary
Pure Bioscience, Inc. entered into a material definitive agreement on September 16, 2024, which involves a direct financial obligation or an off-balance sheet arrangement. The company also reported unregistered sales of equity securities. The filing includes financial statements and exhibits related to these events.
Why It Matters
This filing indicates new financial commitments and potential dilution for shareholders through equity sales, requiring investor attention.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial obligations and shareholder dilution.
Key Players & Entities
- PURE BIOSCIENCE, INC. (company) — Registrant
- September 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-14468 (identifier) — SEC File Number
FAQ
What is the nature of the material definitive agreement entered into by Pure Bioscience, Inc. on September 16, 2024?
The filing indicates the entry into a material definitive agreement, which creates a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant.
Were there any unregistered sales of equity securities by Pure Bioscience, Inc. reported in this filing?
Yes, the filing explicitly states 'Unregistered Sales of Equity Securities' as an item of information.
What is the primary business of Pure Bioscience, Inc. according to the SIC code?
Pure Bioscience, Inc. is classified under 'MISCELLANEOUS CHEMICAL PRODUCTS [2890]'.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated September 16, 2024.
What other information is included in this 8-K filing besides the material agreement and equity sales?
The filing also includes 'Financial Statements and Exhibits'.
Filing Stats: 1,166 words · 5 min read · ~4 pages · Grade level 11.8 · Accepted 2024-09-20 16:45:13
Key Financial Figures
- $500,000 — with an aggregate principal balance of $500,000 (the "Private Placement").The Notes Doc
- $3.0 million — sings for an aggregate offering size of $3.0 million in principal balance. The Notes Docum
- $0.095 — that such conversion price is at least $0.095 per share and less than or equal to $0.
- $0.175 — 095 per share and less than or equal to $0.175 per share, subject to certain customary
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex4-1.htm (EX-4.1) — 20KB
- ex10-1.htm (EX-10.1) — 211KB
- 0001493152-24-037627.txt ( ) — 492KB
- pure-20240916.xsd (EX-101.SCH) — 3KB
- pure-20240916_lab.xml (EX-101.LAB) — 33KB
- pure-20240916_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PURE BIOSCIENCE, INC. Dated: September 19, 2024 By: /s/ Robert Bartlett Robert Bartlett President and Chief Executive Officer (Principal Executive Officer)